Urologic Surgery Research

For enrollment information involving the following trials, please contact a member of our research support staff.

CryoLife

Perioperative Physical Activity (Pedometer)

Frailty Study

Seminoma


CryoLife

Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

Inclusion Criteria:

  • Subjects undergoing open elective urological surgical procedure (on-clamp partial nephrectomy; or radical nephrectomy).

  • Subject is > 22 years of age.

Exclusion Criteria:

  • Subject with known sensitivity to starch or starch-derived materials.

  • Subject who has a clinically significant coagulation disorder or disease, defined as a platelet count <100,000 per microliter, International Normalized Ratio >1.5, or a PTT more than 1.5 times outside the laboratory's normal reference range.

  • Subjects being treated with an investigational product.

Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Kenneth Ogan, MD


Perioperative Physical Activity (Pedometer)

Prospective Randomized Study of Exercise in Patients Undergoing Urologic Surgery

Inclusion Criteria:

  • Adult patients scheduled for operative procedure with an inpatient postoperative stay

  • Willing and able to give blood samples, complete a questionnaire, fill out the step log, and return to clinic for 1st post-operative appointment

Exclusion Criteria:

  • None

Treatment:

Patients are given a pedometer and asked to record their daily steps in a log. The purpose of this study is to determine if pedometers can aid in increasing patients' physical activity during the perioperative period.

Principal Investigators: Kenneth Ogan, MD; Viraj Master, MD, PhD; John Pattaras, MD


Frailty Study

Frailty as a Predictor of Outcomes in Surgical Patients

Inclusion Criteria:

  • Patients already scheduled for major surgery requiring an overnight hospital stay that are willing to do the study’s preoperative assessment tools

  • Patients must be able to give informed consent and be 18 years and older

Exclusion Criteria:

  • Patients diagnosed with severe dementia, Parkinson’s disease, or other functional motor disorders

  • Patients diagnosed with a stroke and who have residual motor and/or cognitive deficits

  • Patients taking carbidopa/levodopa, donepezil hydrochloride, or antidepressant medications

Principal Investigators: Kenneth Ogan, MD; Viraj Master, MD, PhD

Co-Investigators & Collaborators: John Pattaras, MD, and three surgeons from the Department of Surgery: John Sweeney, MD; David Kooby, MD; Shishir Maithel, MD


Seminoma

Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma with Isolated Retroperitoneal Disease (1-2cm)

Inclusion Criteria:

  • Pure seminoma after orchiectomy presenting with isolated retroperitoneal lymphadenopathy

  • Normal serum AFP, β-HCG, LDH (per the local laboratory assay) within 14 days of RPLND

  • Primary tumor excised by radical inguinal orchiectomy and pathology consistent with pure seminoma with negative surgical margins

  • Chest imaging negative for metastasis no more than six weeks prior to the date of RPLND

Exclusion Criteria:

  • Second primary malignancy OR any history of serum AFP elevation

  • Patients receiving any other investigational agent(s)

  • History of receiving chemotherapy or radiotherapy

  • Uncontrolled intercurrent illness: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

Principal Investigator: Mehrdad Alemozaffar, MD

Co-Investigator & Collaborator: Viraj Master, MD, PhD

««return to top